Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 479 of 5804
-
New drug cocktail aims to stall lung cancer
Disease control OngoingThis is a Phase II, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with sintilimab and chemotherapy versus sintilimab combined with chemotherapy in patients with previously untreated locally advanced unresectable or metast…
Phase: PHASE2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for lung cancer: targeted drug BH-30643 enters human trials
Disease control Recruiting nowThis Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 will determine the recommended Phase 2 dos…
Phase: PHASE1, PHASE2 • Sponsor: BlossomHill Therapeutics • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis pain
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a neck surgery slow Alzheimer's? new trial launches
Disease control ENROLLING_BY_INVITATIONThe aim of this study is to evaluate the feasibility, safety, and efficacy of bilateral deep cervical lymphatic trunk decompression combined with mid and deep cervical lymph node-extracervical vein anastomosis in the treatment of patients with Alzheimer's disease. The study seeks…
Phase: NA • Sponsor: Oriental Neurosurgery Evidence-Based-Study Team • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Promising drug duo before bladder removal shows hope for advanced cancer patients
Disease control Recruiting nowThis phase IV trial tests the impact of standard of care enfortumab vedotin and pembrolizumab followed by removal of all or part of the bladder (cytoreductive cystectomy) and/or removal of all or part of the tube that carriers urine from the kidneys to the bladder (ureterectomy) …
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for brain cancer: experimental virus therapy targets aggressive tumors
Disease control Recruiting nowThis is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combi…
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental CAR-T therapy targets tough leukemia
Disease control TerminatedA Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Phase: PHASE1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Poop pills and immunotherapy: a new hope for lung cancer?
Disease control Recruiting nowThis study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo aims to wipe out lingering leukemia before transplant
Disease control Recruiting nowThe purpose of this study is to find out if azacitidine and venetoclax are an effective treatment approach to get rid of or lower measurable residual disease (MRD) in people with acute myeloid leukemia (AML) who have received standard chemotherapy and are planning to have an allo…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to control lung cancer in First-Line patients
Disease control Recruiting nowThis is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in…
Phase: PHASE2, PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for advanced breast cancer: drug combo targets resistant tumors
Disease control OngoingThe purpose of this study is to evaluate the effectiveness and safety of capivasertib + fulvestrant treatment administration in patients with locally advanced (inoperable) or metastatic HR+ / HER2- breast cancer with PIK3CA/AKT1/PTEN-altered following recurrence or progression on…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Light-Activated gel shows promise for rare skin cancer
Disease control TerminatedTo evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Phase: PHASE3 • Sponsor: Soligenix • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New care bundle aims to save lives after brain hemorrhage
Disease control Recruiting nowSpontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, inte…
Phase: PHASE4 • Sponsor: Region Skane • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a transplant drug tame stubborn low platelets in antiphospholipid syndrome?
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacy and safety of sirolimus in patients with anti-phospholipid antibody-associated thrombocytopenia. In the 6-month randomized, double-blind, placebo-controlled phase, participants will receive either sirolimus 1 mg once da…
Phase: PHASE4 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in major trial
Disease control OngoingThis pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial can…
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control OngoingThe purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or prog…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to shrink tough prostate tumors before surgery
Disease control Recruiting nowResearchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advan…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy offers hope for hard-to-treat rectal cancer
Disease control Recruiting nowThis is a prospective study to delve into the therapeutic benefits of combining stereotactic body radiation therapy (SBRT) with PD-1 monoclonal antibody treatment for patients with unresectable locally recurrent rectal cancer (ULRRC). Our aim is to ascertain the safety of this ap…
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to save rectums in advanced cancer patients
Disease control Recruiting nowColorectal cancer ranks as the third most prevalent malignancy worldwide and the second leading cause of cancer-related mortality. For patients with locally advanced rectal cancer (LARC) classified as T3-4/N+ without distant metastasis, achieving organ preservation and functional…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
AI-Powered heart scans aim to predict deadly complications in muscular dystrophy
Knowledge-focused Recruiting nowDystrophin associated heart dysfunction is a leading cause of death in patients with Duchenne and Becker Muscular dystrophy (DMD/BMD) and Duchenne and Becker muscular dystrophy carriers (MDC); however, the evolution of heart dysfunction is not well-understood. The central objecti…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC